| Hormone refractory prostate cancer
Provenge vs Xtandi
Side-by-side clinical, coverage, and cost comparison for hormone refractory prostate cancer.Deep comparison between: Provenge vs Xtandi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXtandi has a higher rate of injection site reactions vs Provenge based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xtandi but not Provenge, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Provenge
Xtandi
At A Glance
IV infusion
Every 2 weeks
Autologous cellular immunotherapy
Oral
Once daily
Androgen receptor inhibitor
Indications
- Hormone refractory prostate cancer
- Hormone refractory prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
- Nonmetastatic Castration-Sensitive Prostate Carcinoma
Dosing
Hormone refractory prostate cancer 3 complete doses at approximately 2-week intervals; each dose infused IV over approximately 60 minutes; premedicate with acetaminophen and antihistamine approximately 30 minutes prior to infusion.
Hormone refractory prostate cancer, Metastatic Castration-Sensitive Prostate Carcinoma 160 mg orally once daily until disease progression or unacceptable toxicity; concurrent GnRH analog or prior bilateral orchiectomy required.
Nonmetastatic Castration-Sensitive Prostate Carcinoma 160 mg orally once daily until disease progression or unacceptable toxicity; GnRH analog may be given with or without XTANDI.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Chills, fatigue, fever, back pain, nausea, joint ache, headache
Serious Acute infusion reactions, cerebrovascular events, eosinophilia, rhabdomyolysis, myasthenia gravis, myositis, tumor flare
Postmarketing Syncope, transient ischemic attack, strokes, hypotension, myocardial infarction, deep venous thrombosis, pulmonary embolism
Most common (>=10%) Musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, fall, fracture, headache
Serious Seizure, posterior reversible encephalopathy syndrome, hypersensitivity, ischemic heart disease, falls and fractures
Postmarketing Vomiting, dysphagia, hypersensitivity (edema of face, tongue, lip, or pharynx), posterior reversible encephalopathy syndrome, dysgeusia, rash, severe cutaneous adverse reactions (Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis)
Pharmacology
PROVENGE is an autologous cellular immunotherapy designed to induce an immune response targeted against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers; APCs are activated ex vivo with the PAP-GM-CSF fusion protein, take up and process the recombinant antigen, and display it on the cell surface to stimulate T cell and antibody responses.
Enzalutamide is an androgen receptor inhibitor that competitively inhibits androgen binding to androgen receptors and consequently inhibits nuclear translocation of androgen receptors and their interaction with DNA; its major metabolite, N-desmethyl enzalutamide, exhibits similar in vitro activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Provenge
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Xtandi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Provenge
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xtandi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Provenge
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Xtandi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ProvengeView full Provenge profile
XtandiView full Xtandi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.